A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):407-411. doi: 10.1007/s10096-020-04016-1. Epub 2020 Aug 27.

Abstract

This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital. During the study period, 2043 patients with suspected COVID-19 were admitted to the emergency department. Molecular tests indicated that 475 of these patients tested positive for COVID-19. We administered hydroxychloroquine plus doxycycline to mild cases (isolated at home) for 3 days and lopinavir plus doxycycline to moderate and severe cases (hospitalized) for 5 days. The overall case fatality rate was 4.2% (20/475).

Keywords: COVID-19; Doxycycline; Favipiravir; Hydroxychloroquine; Lopinavir.

Publication types

  • Retracted Publication

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19 Drug Treatment*
  • Cohort Studies
  • Doxycycline / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxychloroquine / administration & dosage
  • Lopinavir / administration & dosage*
  • Male
  • Middle Aged
  • SARS-CoV-2*

Substances

  • Lopinavir
  • Hydroxychloroquine
  • Doxycycline